Community Practice Connections™: 4th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application

Community Practice Connections™: 4th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application is organized by Physicians' Education Resource, LLC (PER).

Release Date: February 7, 2020
Expiration Date: February 7, 2021

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Activity Overview:
The expansion of immunotherapies into treatment regimens for multiple types of cancer continues to revolutionize the way that clinicians treat their patients and manage treatment-related toxicities. Real-world data and continued collection of clinical trial data on the use of combination therapies, more effective means of mitigating immune-related adverse effects (irAEs), and novel design of clinical trials create educational gaps for busy clinicians who strive to provide care that is at the forefront of clinical knowledge. This field is extremely clinically relevant and encompasses an opportunity for personalized medicine that is ignited with constant drug development in oncology.

This Community Practice Connection™ program is designed to assist clinicians in keeping up-to-date on the frontline developments in immuno-oncology and support innovative best practice treatment for patients with cancer. This online program is associated with the 4th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application, an exciting and fast-paced congress that focuses exclusively on immunotherapies and their application to the management of cancer. This program will provide a comprehensive review of significant data sets that are relevant to the application of novel strategies for the management of several types of cancer. The program will focus on the practical application of recent clinical trial results that directly influence clinical management and biomarker testing.

Topics of particular interest will be combination therapies with checkpoint inhibitors, identification of novel driver mutations, and the application of concepts related to immunotherapy for multiple types of cancer.

Benefits of Participating:
• Utilize the knowledge from experts and clinical trial pioneers on topics related to immune checkpoint blockade, cell-mediated immunotherapy, and clinical trial design.
• Apply additional education to difficult cases or current points of discussion in immunotherapy.
• Incorporate immunotherapy data into daily clinical decision making.
• Explore important concepts related immunotherapy that have broad, practice-changing implications.
• Prepare for possible incidence of short-term and long-term irAEs as applied in clinical scenarios.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Determine current and emerging mechanisms that underlie the rationale to target the immune system to treat various forms of cancer.
• Explain recent evidence that informs the application of immunotherapeutic strategies and how these data can be practically applied to the management of cancer in multiple lines of care.
• Identify next steps in the field of cancer immunotherapies based on key needs, as well as ongoing and planned trials designed to answer important unanswered clinical questions.
• Integrate current and emerging testing approaches to stratify risk and optimize the use of immunotherapeutic strategies.
• Apply knowledge on treatment-related toxicities to proactively mitigate and manage irAEs in patients who receive immunotherapeutic approaches to manage their cancer.